NERV - Minerva Neurosciences, Inc.
| Previous Close | 7.76 |
| Open | 7.83 |
| Bid | 7.80 x 900 |
| Ask | 7.82 x 800 |
| Day's Range | 7.79 - 7.93 |
| 52 Week Range | 5.80 - 12.95 |
| Volume | 43,479 |
| Avg. Volume | 137,170 |
| Market Cap | 305.179M |
| Beta (3Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.29 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
- Thomson Reuters StreetEvents•8 days ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q4 2018 Minerva Neurosciences Inc Earnings Call
- GlobeNewswire•8 days ago
Minerva Neurosciences to Host Webcast Event on Schizophrenia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader.
Motley Fool•14 days agoMinerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
NERV earnings call for the period ending December 31, 2018.
- Associated Press•14 days ago
Minerva Neurosciences: 4Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 34 cents per share. For the year, the company reported that its loss widened to $50.2 million, or $1.29 per share. Minerva Neurosciences shares ...
- GlobeNewswire•14 days ago
Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive.
- GlobeNewswire•21 days ago
Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
WALTHAM, Mass., March 05, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat.
- GlobeNewswire•2 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Wright Medical Group N.V, MSA Safety Incorporporated, Minerva Neurosciences, OSI, Argan, and Approach Resources — New Research Emphasizes Economic Growth
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Simply Wall St.•3 months ago
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- GlobeNewswire•4 months ago
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
“In addition to providing further significant intellectual property protection for MIN-117, the pre-clinical data supporting the application suggest that this compound should be investigated beyond mood and anxiety disorders to include chronic pain, which is often a symptom of several neuro-psychiatric disorders,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Chronic pain is also one of the main reasons cited by patients with MDD who seek medical help,” said Dr. Luthringer.
- GlobeNewswire•4 months ago
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
WALTHAM, Mass., Nov. 21, 2018 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- GlobeNewswire•4 months ago
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256.
- Zacks•4 months ago
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire•4 months ago
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader.
- GlobeNewswire•5 months ago
New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•5 months ago
Minerva Neurosciences: 3Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. Minerva Neurosciences shares have risen 93 percent since the beginning of the year. The stock has increased ...
- GlobeNewswire•5 months ago
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage.
- Simply Wall St.•5 months ago
Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Zacks•7 months ago
J&J Submits NDA to the FDA for Depression Drug in Adults
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
- Benzinga•7 months ago
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
